Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface

ConditionsDry Eye Syndrome Infectious Keratoconjunctivitis Mucous Membrane Pemphigoid Allergic Conjunctivitis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorCentre hospitalier de l'Université de Montréal (CHUM)

About this trial

This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Patients younger than 18 years old;

Patients incapable of giving informed consent.

Trial population

Patients consulting at the cornea service of the ophthalmology department of the CHUM.

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Diagnostic test
During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.

Treatment groups

300 Participants

are divided into 5 treatment groups

Group A: Control group1 intervention

Group B: Dry eye syndrome1 intervention

Group C: Allergic conjunctivitis1 intervention

Group D: Mucous membrane pemphigoid1 intervention

Group E: Infectious keratoconjunctivitis1 intervention

Trial outcomes

Primary outcomes

To obtain the metabolomic and proteomic fingerprint of the studied ocular surface pathologies

Raw data will be analysed with MarkerView software by Sciex to identify specific over- or under-expressed markers in these ocular pathologies.

Time frame

5 years

Secondary outcomes

To objectify changes in metabolomic and proteomic profile associated with topical treatments taken by participants in this study

Raw data will be analysed with the same software to identify specific changes in proteomic and/or metabolomic expression associated with the topical treatments taken by participants in this study.

Time frame

5 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre hospitalier de l'Université de Montréal (CHUM)

Lead sponsor

Université du Québec a Montréal

Collaborator

Source ClinicalTrials.gov

Apply now